Edwards Lifesciences Corporation has recently completed the sale of its
Critical Care division. Despite investigations surrounding possible securities fraud violations, analysts remain bullish on the company's stock, highlighting strong sales growth and positive Q1 2025 earnings among other factors. The company’s
Transcatheter Mitral and Tricuspid Therapies (TMTT) segment has notably exhibited robust growth, contributing to the positive sentiment. Furthermore, Edwards Lifesciences continually outperforms Wall Street estimates, resulting in multiple price target increases from firms such as
Piper Sandler and Baird. The firm's sales outlook for 2025 anticipates revenues over US$5.7 billion, reflecting a bright growth outlook. Particularly, an innovative strategy has boosted Q1 revenues. Nevertheless, there are concerns over class-action lawsuits allegedly involving investor losses, prompting some long-term investors to exercise caution. The company maintains a strong focus on innovation, receiving FDA approval for its
TAVR for patients with asymptomatic severe aortic stenosis, and securing a CE Mark for an innovative Mitral Valve System. Despite considerable volatility, a healthy number of analysts remain bullish on the Edwards Lifesciences stock outlook.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Fri, 16 May 2025 11:00:49 GMT -
Rating 7
- Innovation 9
- Information 8
- Rumor 6
